Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Trump Says Musk Has €Trump Derangement Syndrome€ As Battle Over Bill Heats Up: €Had A Great Relationship…... (Benzinga) +++ TESLA Aktie -3,30%

THERAVANCE BIOPHARMA Aktie

 >THERAVANCE BIO Aktienkurs 
9.4 EUR    (Tradegate)
Ask: 9.5 EUR / 1050 Stück
Bid: 9.3 EUR / 1080 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 8 bis 22 Uhr!
Aktie über LYNX handeln
>THERAVANCE BIO Performance
1 Woche: +19,1%
1 Monat: +5,2%
3 Monate: +12,5%
6 Monate: +5,8%
1 Jahr: +21,8%
laufendes Jahr: +4,6%
>THERAVANCE BIOPHARMA Aktie
Name:  THERAVANCE BIOPHARMA
Land:  China
Sektor:  Gesundheit
ISIN/ Wkn:  KYG8807B1068 / A1137V
Symbol/ Ticker:  0TB (Frankfurt) / TBPH (NASDAQ)
Kürzel:  FRA:0TB, ETR:0TB, 0TB:GR, NASDAQ:TBPH
Index:  -
Webseite:  https://www.theravance.co..
Marktkapitalisierung:  402.58 Mio. EUR
Umsatz:  57.17 Mio. EUR
EBITDA:  -38.51 Mio. EUR
Gewinn je Aktie:  -0.911 EUR
Schulden:  42.18 Mio. EUR
Liquide Mittel:  114.61 Mio. EUR
Umsatz-/ Gewinnwachstum:  6.1% / -
KGV/ KGV lG:  - / 454.55
KUV/ KBV/ PEG:  6.95 / 2.78 / -
Gewinnm./ Eigenkapitalr.:  -89.38% / -31.46%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 264.000 USD.
Suchwörter:  THERAVANCE BIOPHARMA, THERAVANCE BIO
Letzte Datenerhebung:  05.06.25
>Eigentümer
Aktien: 50 Mio. St.
f.h. Aktien: 21.62 Mio. St.
Insider Eigner: 4.54%
Instit. Eigner: 91.75%
>Peer Group

 
05.06.25 - 05:02
 Insiderhandel: SVP, COMM & MEDICAL AFFAIRS verkauft Aktien von Theravance Biopharma im Wert von 264000 USD (Insiderkauf)
 
Farnum, Rhonda - Vorstand - Tag der Transaktion: 2025-06-02...
02.06.25 - 12:03
 Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million (PR Newswire)
 
Definitive agreement to result in one-time $225 million cash payment Theravance Biopharma retains rights to up to $150 million in milestones from Royalty Pharma on Trelegy Ellipta net sales in 2025 and 2026, requiring minimal to no growth over 2024 actuals to be achieved $225 million from......
13.05.25 - 12:03
 Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
 
DUBLIN, May 13, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference in New York City at NASDAQ Tuesday, May 20 at 10:30 AM EDT (7:30 AM PDT / 3:30 PM IST) and will be hosting......
09.05.25 - 18:03
 Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress (PR Newswire)
 
DUBLIN, May 9, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced presentation of analyses of its previous Phase 3 program evaluating ampreloxetine, an investigational medicine for the treatment of symptomatic......
09.05.25 - 01:45
 Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
 
Theravance Bio (TBPH) delivered earnings and revenue surprises of -54.55% and 4.20%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?...
08.05.25 - 22:06
 Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
 
YUPELRI® (revefenacin) net sales of $58.3 million, recognized by Viatris, increased 6% versus Q1 20241 TRELEGY net sales of $854M, as reported by GSK, increased 14% versus Q1 20242 CYPRESS study open label enrollment nearing completion with final patient expected to be enrolled by late......
28.04.25 - 12:03
 Theravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA Congress (PR Newswire)
 
DUBLIN, April 28, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that analyses of the initial Phase 3 program of ampreloxetine (Studies 169 and 170) will be presented at the International MSA Congress, taking place......
24.04.25 - 12:06
 Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025 (PR Newswire)
 
DUBLIN , April 24, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2025 financial results and provide a business update after market close on Thursday, May 8, 2025. An accompanying conference call and simultaneous webcast will be hosted at 5:00......
24.04.25 - 05:01
 Insiderhandel: SVP, COMM & MEDICAL AFFAIRS verkauft Aktien von Theravance Biopharma im Wert von 36000 USD (Insiderkauf)
 
Farnum, Rhonda - Vorstand - Tag der Transaktion: 2025-04-21...
07.04.25 - 21:57
 Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting (PR Newswire)
 
Analyses from Randomized Controlled Trials Further Support the Target Engagement and Safety Profile of Ampreloxetine in Neurodegenerative Disease DUBLIN, April 7, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new......
31.03.25 - 12:01
 Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
 
DUBLIN, March 31, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a fireside chat at the Jones Healthcare and Technology Innovation Conference in Las Vegas on Wednesday, April 9 at 11:30 am PDT (2:30 pm EDT/6:30 PM GMT). Members of Theravance Biopharma......
28.03.25 - 18:00
 Why Is Theravance Bio (TBPH) Up 0.4% Since Last Earnings Report? (Zacks)
 
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues....
27.03.25 - 11:03
 Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology (PR Newswire)
 
DUBLIN, March 27, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new analyses of the initial Phase 3 program of ampreloxetine (Studies 169 and 170) supporting its selective and differentiated pharmacodynamic profile......
27.02.25 - 01:00
 Theravance Biopharma (TBPH) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
 
Theravance Bio (TBPH) delivered earnings and revenue surprises of 0% and 3.50%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?...
26.02.25 - 22:27
 Theravance Biopharma GAAP EPS of -$0.31 misses by $0.11, revenue of $18.75M beats by $1.66M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
26.02.25 - 22:06
 Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
 
YUPELRI® (revefenacin) US net sales, recognized by Viatris, reached an all-time high of $66.7 million in Q4 2024 and $238.6 million in FY 2024, up 10% and 8%, respectively, compared with 20231 FY 2024 TRELEGY Net Sales, as reported by GSK, of $3.46 billion, up 26% compared with 2023 and......
27.01.25 - 11:30
 Theravance Bio (TBPH) Soars 8.3%: Is Further Upside Left in the Stock? (Zacks)
 
Theravance Bio (TBPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term....
24.01.25 - 02:01
 Insiderhandel: SVP, COMM & MEDICAL AFFAIRS verkauft Aktien von Theravance Biopharma im Wert von 36000 USD (Insiderkauf)
 
Farnum, Rhonda - Vorstand - Tag der Transaktion: 2025-01-21...
12.12.24 - 18:48
 Theravance Bio (TBPH) Up 3.7% Since Last Earnings Report: Can It Continue? (Zacks)
 
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues....
20.11.24 - 12:02
 Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
 
DUBLIN, Nov. 20, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3 at 11:15 am EST (8:15 am PST/4:15 pm GMT) and will be hosting in-person meetings with the investment......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Kein Kaiser kann, was unser ist, verschenken. - Friedrich Johann Christoph Schiller
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!